If you are weighing a medical screening trip to China, the question that used to matter most was whether the scanner and the lab were modern. In 2026 a second question has become unavoidable: whether the artificial intelligence reading those images is itself a registered, inspected medical device. Guidance issued over the past year has moved Chinese hospital AI out of the pilot-project category and into a compliance-and-evidence category. That shift changes what an international patient can reasonably expect to carry home in a report — and what a physician in another country can be asked to accept.
This guide explains the regulatory milestone in plain terms, lists the specific tools that have reached it, and sets out a due-diligence checklist for a short-stay screening or pathology-review trip.
Why the "Class III" milestone changes the decision, not just the marketing
Chinese medical device classification puts Class III at the highest control level, reserved for products where the risk to patients demands the most rigorous review. The scale of what has already been cleared is the headline: as of October 2025, the National Medical Products Administration had approved more than 110 Class III standalone software products built on deep learning, spanning nine types of data, according to a regulatory analysis by Global Law Office.
Two documents drive the practical change. The NMPA's inspection centre published a draft set of inspection key points for AI medical devices on 8 October 2026, with the comment period closing 28 October 2026. Before that, the centre for device evaluation issued a draft 2026 revision of the guiding principles for AI medical device registration review on 14 September 2026, closing 12 October 2026. The revised Good Manufacturing Practice standard for medical devices took effect on 1 November 2026.
For a patient, the significance is not the paperwork. It is that data and algorithms were pulled into the scope of production rather than treated as software features. Concretely, the framework requires training, tuning and test datasets to be pairwise non-overlapping, with de-duplication checks retained as records. That is the kind of requirement that produces auditable artefacts — which is exactly what an overseas consultant asks for when reviewing a foreign report.
What traceability buys you across borders
A report from an uninspected algorithm is a printout. A report generated with a registered device can be walked backwards: which acquisition protocol, which dataset, which software version, which clinician signed it. When you fly home and hand the file to your own doctor, the question they ask is rarely "is this AI advanced?" It is "can I verify this?" Registration makes verification conceivable, and that materially raises the chance the findings are accepted rather than repeated.
What has actually been cleared, and what is still in review
Precision matters here, because several products in this space are at different regulatory stages, and conflating them is the most common error in patient-facing write-ups.
| Product or category | Clinical use | Regulatory stage reported | Evidence noted in the source |
|---|---|---|---|
| Chromosome karyotype assistance software (AI AutoVision) | Cytogenetic analysis support | Class III registration certificate | Reported as the first certificate for a large-model-based medical device; multicentre prospective study of 1,734 cases |
| Cervical cell digital pathology image assistance | Cervical cytology screening support | Class III registration certificate | Cleared product, cited in the same review |
| Gastric lesion endoscopic image triage | Triage support during upper GI endoscopy | Class III registration certificate | Cleared product, cited in the same review |
| Chest CT "one scan, many checks" agent | Screens a single chest CT for close to 100 types of abnormal findings | Entered the innovative medical device special review procedure — a pathway, not yet a granted certificate | Reported as China's first large-model, multi-disease AI product in that channel; a United Imaging Intelligence project with the Shanghai medical AI pilot base |
The last row deserves emphasis. A multi-disease chest CT product is the feature most likely to attract a screening traveller, because one acquisition covering many lesion types fits a compressed itinerary. But entering an expedited review channel is a step toward market authorisation, not the authorisation itself. If a clinic tells you a product is "in the innovation channel," ask whether the certificate has been issued and note the difference in your own file.
How the 2026 rules touch the report you receive
Three provisions have direct patient-facing consequences.
Synthetic images cannot stand alone. Generated or reconstructed images produced by a model may not be used as the sole basis for a diagnosis, and their use must be disclosed both in the software interface and in the instructions for use. Practically: if an image in your file looks unusually clean, unusually noise-free, or is labelled as generated, that label is mandated — and the diagnostic weight belongs to the original acquisition plus the clinician's read.
Algorithms are now inspected where they are made. The inspection-key-points approach treats the algorithm and its data pipeline as part of production quality, subject to on-site checking. It is the move from "the software was approved once" to "the software is still being made the way it was approved."
Evidence must be prospective and multicentre where claimed. The karyotype example — a prospective study across multiple centres with 1,734 enrolled cases — illustrates the evidentiary bar that a cleared product had to meet, versus the anecdotal performance claims typical of unregulated wellness screening.
| If you are here for... | What AI realistically adds | What still requires a human |
|---|---|---|
| Imaging-based screening | Pattern detection across many lesion types from one scan, flagging low-suspicion findings a human read may deprioritise | Correlating flags with history, ordering confirmation, deciding significance |
| Check-up package | Throughput and consistency on high-volume sequences such as chest CT and cervical cytology | Interpreting incidentalomas and communicating uncertainty |
| Pathology review | Digital slide triage and assisted analysis in cleared applications | Re-read of the slide, integration with clinical context, final diagnosis |
None of this alters the fundamental point: a specific treatment plan must be assessed by a licensed physician in person, after examination and review of your complete records. Screening output is an input to that consultation, not a substitute for it.
Building a short-stay trip around this
The appeal of multi-disease imaging tools for international patients is arithmetic rather than technological. A visit with five to seven clinic days cannot comfortably absorb separate appointments for each organ system. One chest CT that a registered tool then screens across close to 100 findings concentrates the acquisition step, leaving later days for confirmatory tests and specialist consultation. See our health check-ups in China overview for how packages are structured, and the practical notes in health check-ups in Shanghai for foreigners.
Two cautions that come with compression. First, more flagged findings means more downstream confirmation, and confirmatory work — contrast studies, endoscopy, biopsy, molecular testing — is what actually consumes calendar days. Build buffer time rather than packing more tests into the first 48 hours. Second, if your purpose is cancer-directed rather than general screening, the imaging is only step one; the therapeutic pathway, including cancer treatment in China, depends on a stage and a histological diagnosis, which AI flagging does not supply.
Booking across departments in a large public hospital is where foreign patients most often lose days to language and queueing rather than to medicine. Our hospital appointment service for Shanghai exists for exactly that gap, and the broader logistics — documents, insurance questions, sequencing — are covered in the complete medical tourism guide for China and the medical visa guide.
Six questions to ask before you book a screening trip
- Which registered software will read my study, and does it hold a Class III certificate now, or is it in a review procedure?
- Will my file include the original source data — DICOM images, whole-slide files — and not only a summary printout?
- Who signs the report, in what department, and is the signature or reviewer credential stated?
- If the report references any generated or synthetic image, is that disclosed, and is the original acquisition also included?
- Can pathology or imaging records from my home country be accepted for review without repeating the acquisition, and what format do they need?
- How many days of confirmation work are realistically likely after the screening results, and does my visa window cover them?
Ask these in writing, through a coordinator who can put them to the department rather than to a marketing desk. Compare hospitals before committing; the hospital directory shows where international departments and specialized pathology capacity actually sit.
Where the honest bottom line is
China's AI imaging and pathology tools are no longer experimental curiosities shown to visitors. More than a hundred Class III deep-learning software products have been approved, several in exactly the screening applications a foreign patient would buy, and the inspection regime now reaches data provenance and algorithm production. That is a real reason for a report produced here to travel better.
It is not a reason to expect a diagnosis from an algorithm, to treat a special-review submission as a cleared product, or to skip the confirmatory step. The patients who get the most from a compressed screening trip are the ones who arrive with source records, ask which software is certified, leave with verifiable data rather than a printout, and hold a home-country consultation on the other side.
OriEast can help with the practical layer: submitting your history for a case evaluation so you know before you fly whether a Chinese department would review your imaging or pathology material, and sending an inquiry about translation, appointment booking and day-to-day coordination on the ground. Medical interpretation, hospital scheduling and care coordination are the services we provide, and we will tell you plainly when a test is unlikely to change your management.